Yu Cao

ORCID: 0000-0002-9646-762X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Growth Hormone and Insulin-like Growth Factors
  • Nail Diseases and Treatments
  • Fungal Infections and Studies
  • Wound Healing and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Atherosclerosis and Cardiovascular Diseases
  • Signaling Pathways in Disease
  • Cancer Research and Treatments
  • Bee Products Chemical Analysis
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Antifungal resistance and susceptibility
  • Advancements in Transdermal Drug Delivery
  • Sarcoma Diagnosis and Treatment
  • Skin Protection and Aging
  • FOXO transcription factor regulation
  • Pharmacy and Medical Practices
  • Acute Ischemic Stroke Management
  • Lymphoma Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Pharmaceutical Practices and Patient Outcomes
  • Autophagy in Disease and Therapy
  • Intergenerational Family Dynamics and Caregiving
  • Medication Adherence and Compliance

First People's Hospital of Yunnan Province
2024

Guiyang Medical University
2015-2022

Fudan University
2021

National Health and Family Planning Commission
2021

Children's Hospital at Montefiore
2014

Albert Einstein College of Medicine
2011-2014

Background Survival outcomes for patients with osteosarcoma (OS) have remained stagnant over the past three decades. Insulin-like growth factor 1 receptor (IGF1R) is over-expressed in a number of malignancies, and anti-IGF1R antibodies are currently being studied clinical trials. Understanding molecular aberrations which result increased tumor response to therapy could allow selection most likely benefit from IGF1R targeted therapy. Methods mRNA expression was assessed by RT PCR OS patient...

10.1371/journal.pone.0106249 article EN cc-by PLoS ONE 2014-08-29

According to China's Seventh National Census, 18.70% of a total 1.41 billion people were 60 or older and 13.50% 65 older, so population is increasingly aging. In conjunction with socioeconomic scientific technological development its promotion medical insurance-related policies, rational medication management for the elderly concern in order control risk polypharmacy. This paper summarizes discusses following five key issues inherent management: i) an increase serious polypharmacy potential...

10.5582/bst.2021.01254 article EN BioScience Trends 2021-06-30

Objective. To explore the effect and potential mechanism of T-LAK cell-originated protein kinase (TOPK) on autophagy in cutaneous squamous cell carcinoma (cSCC). Methods. Human cSCC cancer tissue paracancerous samples were collected clinically; immunohistochemistry was used to detect expression TOPK, nuclear factor κB p65 (NF-κB p65), phosphorylated inhibitor α (p-IκBα), Beclin-1, microtubule-associated 1 light chain 3 (LC3) tissue; immunofluorescence adopted coexpression NF-κB p65, p-IκBα,...

10.1155/2022/3771711 article EN Disease Markers 2022-06-15

Background: Previous studies have revealed that remote ischemic conditioning (RIC) may a neuroprotective function. However, the potential benefit of RIC for patients with ICH remain unclear. Objective: The primary aim this study is to assess safety and efficacy ICH. Methods: Safety Efficacy Spontaneous (SERIC-ICH) an ongoing prospective, randomized, multicenter, parallel-controlled, blinded-endpoint clinical trial. will enroll estimated 2000 aged ⩾18 years within 24 h after onset, National...

10.1177/23969873231201712 article EN European Stroke Journal 2023-09-26

Abstract To address the need for novel osteosarcoma (OS) treatment regimens with greater efficacy and less toxicity, attention has been focused on developing antibodies that target components of insulin-like growth factor (IGF) pathway, particularly 1 receptor tyrosine kinase (IGF1R). IGF1R its two ligands, (IGF1) 2 (IGF2), are known to be over-expressed in several cancers including OS have roles regulating cellular proliferation. Clinical trials IGF1R-inhibiting antibody therapies OS,...

10.1158/1538-7445.am2011-1208 article EN Cancer Research 2011-04-01
Coming Soon ...